NicOx SA

278 articles about NicOx SA

• Nicox Provides Third Quarter 2021 Business and Financial Highlights

  10/19/2021

  Nicox SA, an international ophthalmology company, provided business and financial highlights for Q3 2021 for Nicox SA and its subsidiaries as well as key expected value-inflection milestones.

• Nicox to present at the OIS Glaucoma Virtual Innovation Showcase

  10/13/2021

  Nicox SA, an international ophthalmology company, announced that Mr Michele GARUFI, Chairman and Chief Executive Officer of Nicox, will present at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase being held virtually on October 21, 2021.

• Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model

  9/29/2021

  Nicox SA, an international ophthalmology company, reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1.

• Nicox First Half 2021 Financial Results and Business Update

  9/27/2021

  Nicox SA, an international ophthalmology company, reported the financial results for Nicox SA and its subsidiaries for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs.

• Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial

  9/23/2021

  Nicox SA, an international ophthalmology company, announced the results from its Mississippi Phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations of blepharitis.

• Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update

  7/16/2021

  Nicox SA, an international ophthalmology company, provided business and financial highlights for Q2 2021 for Nicox SA and its subsidiaries as well as an update on its strategy and key expected value-inflection milestones.

• Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board

  7/13/2021

  Nicox SA, an international ophthalmology company, announced that two internationally recognized experts in glaucoma, Robert N. Weinreb, M.D., Distinguished Professor and Chair, Ophthalmology and Director, Shiley Eye Institute, University of California San Diego, and Sanjay G. Asrani, M.D., Professor of Ophthalmology, Duke University, will be joining the Nicox Glaucoma Clinical Advisory Board.

• Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement

  7/5/2021

  Nicox SA, an international ophthalmology company, announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE®, 0.24% in the Chinese and the majority of South East Asian markets.

• Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial

  7/2/2021

  Nicox SA, an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period.

• Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial

  7/1/2021

  Nicox SA, an international ophthalmology company, presented results from the Dolomites Phase 2 clinical trial showing that NCX 470, a novel nitric oxide -donating prostaglandin analog, produced significantly greater intraocular pressure lowering effects in glaucoma patients compared with the current standard of care, latanoprost.

• Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

  6/25/2021

  Nicox SA, an international ophthalmology company, announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA®, 0.024% in the United Arab Emirates.

• Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial

  6/1/2021

  Nicox SA announced that, more than 200 patients, the pre-defined target, have been randomized in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial. Top-line results are expected to be announced during September 2021.

• Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico

  5/5/2021

  Nicox SA, an international ophthalmology company, announced the signature of an exclusive license agreement with Laboratorios Grin, a wholly-owned subsidiary of Lupin Limited, for the registration and commercialization of ZERVIATETM, 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in Mexico.

• Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar

  5/4/2021

  Press Release Nicox’s Licensee Bausch + Lomb Launches VYZULTA®(latanoprostene bunod ophthalmic solution), 0.024%in Taiwan and Receives Approval in Qatar

• 

  BioSpace Global Roundup, June 4

  6/4/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!
• 

  Biotech Movers and Shakers Aug. 27

  8/27/2018

  Who made a splash in the biotech world this week? Here are some notable people.

• Nicox Appoints Tomas Navratil, Ph.D., as Head of Development

  1/3/2018

  Dr. Navratil will be responsible for leading all of the Company's non-clinical and clinical development activities.

• Nicox Highlights VYZULTA Approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives

  11/3/2017

  The company provided an overview yesterday.

• Bausch & Lomb and Nicox Announce FDA Approval of VYZULTA (latanoprostene Bunod Ophthalmic Solution), 0.024%

  11/2/2017

  Valeant wholly owned subsidiary, Bausch & Lomb a leading global eye health company, and NicOx SA  today announced that the FDA has approved the NDA for VYZULTA.